The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
The triplet combination of bortezomib, cyclophosphamide and dexamethasone (VCd) has been found to be well-tolerated and provide high response rates in patients with newly diagnosed multiple myeloma (NDMM) making it a suitable option for induction therapy in both transplant eligible and ineligible patients. To date, there has been no standard dosing protocol for VCd due to inconsistent trial results.
Daratumumab, an anti-CD38 monoclonal antibody, shows high efficacy when combined with other regimens. Recently, daratumumab in combination with bortezomib, melphalan and, prednisone (d-VMP) was approved in the frontline setting for patients ineligible for autologous stem cell transplant (ASCT).1 However, since this is not commonly used it is necessary to establish the efficacy of daratumumab in other combinations, especially for patients with NDMM.
Habte Yimer, Texas Oncology-Tyler/US Oncology Research, Tyler, TX, and colleagues conducted a single-arm, open-label, multicenter, phase II study (LYRA, MMY2012, NCT02951819) investigating the regimen of daratumumab with VCd (D-VCd) in patients with NDMM and relapsed MM (RMM). Additionally, the effect of administering the first dose of daratumumab as a split dose was evaluated.2
Data given as NDMM versus RMM
|
NDMM (n = 86): |
RMM (n = 14): |
---|---|---|
After 4 cycles of induction |
|
|
CR + VGPR |
44.2% (95% CI, 33.5–55.3%) |
57.1% (95% CI, 28.9–82.3%) |
CR |
4.7% (n = 4) (95% CI, 1.3–11.5%) |
14.3% (n = 2) (95% CI, 1.8–42.8%) |
ORR |
79.1% (95% CI, 69.0–87.1%) |
71.4% (95% CI, 41.9–91.6%) |
At the end of induction |
|
|
CR + VGPR |
55.8% (n = 48) (95% CI, 44.7–66.5%) |
64.3% (n = 9) (95% CI, 35.1–87.2%) |
CR |
9.3% (n = 8) (95% CI, 4.1–17.5%) |
21.4% (n = 3) (95% CI, 4.7–50.8%) |
ORR |
81.4% (95% CI, 71.6–89.0%) |
71.4% (95% CI, 41.9–91.6%) |
Table 1: Rates of CR + VGPR, CR and ORR
|
NDMM (n = 86): |
RMM (n = 14): |
---|---|---|
Median time to PR or better |
1.0 month (95% CI, 1.0–1.0) |
1.0 month (95% CI, 0.9–not evaluable [NE]) |
Median time to VGPR or better |
4.6 months (95% CI, 2.8–6.4) |
1.8 months (95% CI, 1.0–NE) |
Median DoR |
Not reached (NR)
|
12.4 months (95% CI, 3.7–12.4) |
Median PFS (n = 87) |
NR |
13.3 months (95% CI, 6.8–13.3) |
Twelve-month PFS |
87.0% (95% CI, 57.1–96.6%) |
66.2% (95% CI, 32.4–86.0%) |
Twelve-month OS |
98.8% (95% CI, 92.0–99.8%) |
54.5% (95% CI, 8.6–86.1%) |
Table 2: Efficacy results; time to PR or >VGPR, DoR, PFS and OS
|
NDMM (n = 86) |
RMM (n = 14) |
---|---|---|
Most frequent treatment-emergent adverse event (TEAE) of any grade |
Fatigue (61.6%) |
Fatigue, diarrhea and upper respiratory tract infection (42.9% each) |
Most frequent TEAE grade 3/4 |
Neutropenia (11.6%)
|
Neutropenia (21.4%) |
Serious TEAEs |
19 patients |
2 patients |
Most frequent serious TEAE (occurred in ≥2 patients) |
Atrial fibrillation (3.5%) Pulmonary embolism (2.3%) Bacteraemia (2.3%) Mental status changes (2.3%) |
NR |
Serious TEAEs related to daratumumab |
3 patients Bacteraemia (n = 1) Viral upper respiratory tract infection (n = 1) Vomiting (n = 1) |
None |
Table 3: Safety results
References